|
LARP7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
4.37070379888382E-11 |
| Normal-vs-Stage3 |
2.77555756156289E-15 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
5.149600E-01 |
| Stage1-vs-Stage3 |
1.245350E-01 |
| Stage1-vs-Stage4 |
1.577530E-03 |
| Stage2-vs-Stage3 |
6.710400E-01 |
| Stage2-vs-Stage4 |
1.174020E-01 |
| Stage3-vs-Stage4 |
1.678380E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.72189998212968E-09 |
| Normal-vs-Asian |
2.98449998048511E-09 |
| Caucasian-vs-AfricanAmerican |
8.800800E-01 |
| Caucasian-vs-Asian |
1.538820E-01 |
| AfricanAmerican-vs-Asian |
2.979600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
2.326000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
8.10020000000522E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.133200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.539700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.046000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.855800E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.059200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.944600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.590100E-02 |
| Classical-VS-Follicular |
3.354000E-01 |
| Classical-VS-Other |
9.826800E-01 |
| Classical-VS-Normal |
2.07511785532688E-12 |
| Tall-VS-Follicular |
1.058120E-02 |
| Tall-VS-Other |
3.004000E-01 |
| Tall-VS-Normal |
1.76125780626535E-12 |
| Follicular-VS-Other |
7.526200E-01 |
| Follicular-VS-Normal |
1.57260005018145E-09 |
| Other-VS-Normal |
1.278270E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.81632486828676E-13 |
| N0-vs-N1 |
3.271200E-01 |
|
|
